Changes in Hong Kong stocks | Chinese herbal medicine leader Xinhehua (02206) surged more than 30% to a record high of more than 1.85 times higher than the offering price

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that New Lotus (02206) surged more than 30% against the market and hit a new listing high of HK$114.8, which is more than 1.85 times higher than the offering price of HK$40.2. As of press release, it rose 29.16% to HK$110.3, with a turnover of HK$41.075 million.

New Lotus is the core supplier of large-scale Chinese medicine tablets in China. It has two major products: ordinary Chinese medicine tablets and toxic tablets, with a total of more than 770 types and more than 4,900 products, and has more than 1,000 customers in hospitals, medical institutions and large pharmacy chains in China. According to the sales revenue of Chinese herbal medicine products in 2025, the company ranked 2nd in the industry nationwide.

In terms of performance, from 2023 to 2025, the company's revenue was 1,146 billion yuan, 1,249 million yuan and 1,335 billion yuan; revenue for the first four months of this year was 432 million yuan, up 12.9% year on year; net profit was 33.9 million yuan, up 63.8% year on year; gross margin was restored to 21.8% from 17.1% in 2024. The profit growth rate far exceeds the revenue growth rate. The core is due to the decline in the cost of core raw materials such as Huanglian, Chuan Beimu, and French Banxia, as well as the scale effect brought about by the volume of collection and release.